비피도박테리움 CBT BG7, BR3, BL3의 진세노사이드 전환능
Bioconversion of Ginsenosides by Bifidobacterium CBT BG7, BR3 and BL3
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
본 연구에서는 한국형 프로바이오틱스와 홍삼을 발효하여저분자 진세노사이드인 compound K (CK)로 생물전환되는지를 확인하였다. 프로바이오틱스 19종의 유전체 분석결과, 진세노사이드 Rb1에서 CK로 전환에 관련된 β-glucosidase 는 19종 모든 균주에서 확인되었고, α-arabinofuranosidase 유전자는 3종의 균주, β-xylosidase는 6종 균주, α-rhamnosidase 는 8종의 균주에서 확인되었다. 이 중 B. longum CBT BG7는 Rb1으로부터 CK까지 전환시켜, CK 함량을 증가시켰다. 또한, B. breve CBT BR3와 B. lactis CBT BL3은 Rb1을Rd로 전환시켰다. 균체를 파쇄 또는 미파쇄하여 진세노사이드 전환 반응을 비교했을 때 미파쇄물이 F2와 CK로의 높은전환량과 수율을 보였다. CBT BG7 + BL3와 BG7 + BR3 혼합균주는 CBT BG7 단독보다 진세노사이드 F2의 함량을 증가시켰다. CBT BG7과 α-amylase 효소를 함께 반응하였을 때에 F2 함량이 증가되었다. 본 연구는 한국형 프로바이오틱스인 CBT BG7, BR3, BL3와 홍삼을 함께 섭취할 경우, 건강에 도움을 주는 생리활성물질인 CK의 생산을 확인하였다. 추후 부탄올 등 다양한 추출용매를 활용하여 생물전환 효율및 CK로의 전환율에 대한 추가 연구가 필요해 보인다.
Abstract
In this study, we identified that the fermentation of Korean indigenous probiotics and red ginseng produced ginsenoside compound K (CK) from major ginsenosides. Based on whole genome sequencing of 19 probiotics species, β-glucosidase, α-arabinofuranosidase, β-xylosidase, and α-rhamnosidase related to bioconversion of ginsenosides are identified in the genome of 19 species, 3 species, 6 species, and 8 species, respectively. Among the 19 probiotics species, Bifidobacterium longum CBT BG7 converted from ginsenoside Rb1 to CK, and both B. breve CBT BR3 and B. lactis CBT BL3 converted ginsenoside Rb1 to Rd. The final concentration and yield of ginsenoside F2 and CK were higher in the fermentation with the nondisrupted cells than with disrupted cells. The combination of both CBT BG7 and BL3, and CBT BG7 and BR3 showed higher amounts of F2 than CBT BG7 only. CBT BG7 with adding α-amylase increased the amounts of F2. In this study, we identified that the fermentation of both Korean indigenous probiotic bacteria CBT BG7, BR3 and BL3, and red gingseng is able to produce CK, a bioactive compound that promotes health benefits.
참고문헌 (28)
- 박사윤, "Systems-level mechanisms of action of Panax ginseng: a network pharmacological approach", Journal of Ginseng Research, 42(1), pp.98~106 (2018), 고려인삼학회[DOI]
- 박영철, "홍삼의 약리와 독성 기전에 대한 고찰", 대한한의학회지, 33(3), pp.200~230 (2012), 대한한의학회
- Yang XD, "A review of biotransformation and pharmacology of ginsenoside compound K", Fitoterapia, 100, pp.208~220 (2015)
- Ganesan P, "Recent trends of nano bioactive compounds from ginseng for its possible preventive role in chronic disease models", RSC Adv, 5, pp.98634~98642 (2015)
- Christensen LP, "Biomass and content of ginsenosides and polyacetylenes in American ginseng roots can be increased without affecting the profile of bioactive compounds", J. Nat. Med, 63, pp.159~168 (2009)
- Park H, "The role of gut microbiota in ginsenoside metabolism and biotransformation of ginsenoside by lactic acid bacteria", Curr. Top. Lact. Acid Bact. Probiotics, 5, pp.1~12 (2019)
- Shibata S, "Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds", J. Korean Med. Sci, 16(Suppl), pp.S28~S37 (2001)
- Han MH, "Bioconversion of ginseng using nicroorganisms", J. Biotechnol. Bioind, 7, pp.5~11 (2019)
- Akao T, "Appearance of compound a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration measurement of compound K by enzyme immunoassay", Biol. Pharm. Bull, 21, pp.245~249 (1998)
- Dong-Hyun Kim, "Metabolism of Ginsenosides to Bioactive Compounds by Intestinal Microflora and Its Industrial Application", Journal of Ginseng Research, 33(3), pp.165~176 (2009), 고려인삼학회
- Lee J, "Studies on absorption, distribution and metabolism of ginseng in humans after oral administration", J. Ethnopharmacol, 122, pp.143~148 (2009)
- Santangelo R, "Ginsenosides, catechins, quercetin and gut microbiota : Current evidence of challenging interactions", Food Chem. Toxicol, 123, pp.42~49 (2019)
- Bai L, "Therapeutic potential of ginsenosides as an adjuvant treatment for diabetes", Front. Pharmacol, 9, pp.423~ (2018)
- Yao H, "Effects of compound K, an enteric microbiome metabolite of ginseng, in the treatment of inflammation associated colon cancer", Oncol. Lett, 15, pp.8339~8348 (2018)
- Wang CZ, "Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer", Int. J. Oncol, 40, pp.1970~1976 (2012)
- Kyung Hoon Chang, "Evaluation of glucosidases of Aspergillus niger strain comparing with other glucosidases in transformation of ginsenoside Rb1 to ginsenosides Rg3", Journal of Ginseng Research, 38(1), pp.47~51 (2014), 고려인삼학회[DOI]
- Quan K, "Rapid preparation of rare ginsenosides by acid transformation and their structure activity relationships against cancer cells", Sci. Rep, 5, pp.8598~ (2015)
- Myung Kyum Kim, "Microbial Conversion of Major Ginsenoside Rb1 to Pharmaceutically Active Minor Ginsenoside Rd", The Journal of Microbiology, 43(5), pp.456~462 (2005), 한국미생물학회
- Kim CK, "Ginseng sponins processing by using bio-conversion technology", J. Ginseng Res, 6, pp.3~13 (2012)
- 유재명, "Enhanced production of compound K in fermented ginseng extracts by Lactobacillus brevis", Food Science and Biotechnology, 28(3), pp.823~829 (2019), 한국식품과학회[DOI]
- 박보연, "Evaluation of ginsenoside bioconversion of lactic acid bacteria isolated from kimchi", Journal of Ginseng Research, 41(4), pp.524~530 (2017), 고려인삼학회[DOI]
- 김지현, "향신료의 유산균 생장 촉진 효과와 홍고추(Capsicum annuum L.) 발효 산물의 HT-29 세포에서의 Tight Junction Protein 유전자 발현 조절 확인", 한국식품영양과학회지, 50(1), pp.16~28 (2021), 한국식품영양과학회
- Korea Health Supplements Association, "Health Functional Foods Code II", pp.351~355 (2022), KHSA
- 구석모, "Effects of ascorbic acid on a-L-arabinofuranosidase and a-Larabinopyranosidase activities from Bifidobacterium longum RD47 and its application to whole cell bioconversion of ginsenoside", Applied Biological Chemistry, 58(6), pp.857~865 (2015), 한국응용생명화학회
- Bae EA, "Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria", Biol. Pharm. Bull, 23, pp.1481~1485 (2000)
- Seockmo Ku, "Whole-Cell Biocatalysis for Producing Ginsenoside Rd from Rb1 Using Lactobacillus rhamnosus GG", Journal of Microbiology and Biotechnology, 26(7), pp.1206~1215 (2016), 한국미생물·생명공학회[DOI]
- Jeon-Kyung Kim, "Effects of gut microbiota on the pharmacokinetics of protopanaxadiol ginsenosides Rd, Rg3, F2, and compound K in healthy volunteers treated orally with red ginseng", Journal of Ginseng Research, 44(4), pp.611~618 (2020), 고려인삼학회[DOI]
- Kim NM, "Effect of α-amylase on the qualities of red ginseng extract", J. Ginseng. Res, 24, pp.153~156 (2000)